417717-21-6 Usage
Description
Lenvatinib Impurity f, also known as Desamino Hydroxy Lenvatinib, is a derivative compound of Lenvatinib (L329400). It is characterized by its function as a reagent for the synthesis of urea derivatives containing nitrogenous aromatic ring compounds. These synthesized compounds serve as angiogenesis inhibitors, which are crucial in the treatment of various diseases.
Uses
Used in Pharmaceutical Industry:
Lenvatinib Impurity f is used as a reagent for the synthesis of urea derivatives that contain nitrogenous aromatic ring compounds. These compounds are essential in the development of angiogenesis inhibitors, which play a significant role in the treatment of diseases.
Used in Oncology:
Lenvatinib Impurity f is used as an orally active inhibitor of multiple receptor tyrosine kinases, including VEGF, FGF, and SCF receptors. By targeting these receptors, it helps in the treatment of various types of cancer and potentially contributes to the development of novel therapeutic strategies for cancer patients.
Check Digit Verification of cas no
The CAS Registry Mumber 417717-21-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,1,7,7,1 and 7 respectively; the second part has 2 digits, 2 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 417717-21:
(8*4)+(7*1)+(6*7)+(5*7)+(4*1)+(3*7)+(2*2)+(1*1)=146
146 % 10 = 6
So 417717-21-6 is a valid CAS Registry Number.
417717-21-6Relevant articles and documents
Lenvatinib-zinc phthalocyanine conjugates as potential agents for enhancing synergistic therapy of multidrug-resistant cancer by glutathione depletion
Wei, Gaofei,Huang, Liangfeng,Jiang, Yali,Shen, Yifeng,Huang, Zeqian,Huang, Yanjuan,Sun, Xiaoqi,Zhao, Chunshun
, p. 53 - 64 (2019/03/08)
The therapeutic efficacy of targeted therapy is dramatically hindered by multidrug resistance (MDR) because of elevated GSH levels. Thus, depletion of intracellular GSH level is highly desirable for targeted-therapeutic agents to reverse tumor drug resist
Nitrogen-containing aromatic derivatives
-
, (2008/06/13)
Compounds represented by the following general formula: [wherein Ag is an optionally substituted 5- to 14-membered heterocyclic group, etc.; Xg is —O—, —S—, etc.; Yg is an optionally substituted C6-14 aryl group, an optionally substituted 5- to 14-membered heterocyclic group, etc.; and Tg1 is a group represented by the following general formula: (wherein Eg is a single bond or —N(Rg2)—, Rg1 and Rg2 each independently represent a hydrogen atom, an optionally substituted C1-6 alkyl group, etc. and Zg represents a C1-8 alkyl group, a C3-8 alicyclic hydrocarbon group, a C6-14 aryl group, etc.)], salts thereof or hydrates of the foregoing.
